ACADIA Pharmaceuticals to Present Preclinical Data on Its Advanced Schizophrenia Programs at the 37th Annual Meeting of the Society for Neuroscience
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel
Originally Syndicated via RSS from Business Wire Health: Mental Health News